A number of firms have modified their ratings and price targets on shares of Stryker (NYSE: SYK) recently:

  • 12/1/2017 – Stryker was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/24/2017 – Stryker was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating.
  • 11/17/2017 – Stryker had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $161.00 price target on the stock.
  • 11/16/2017 – Stryker was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $173.00 price target on the stock, up previously from $161.00.
  • 11/14/2017 – Stryker was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/3/2017 – Stryker had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 10/30/2017 – Stryker was given a new $156.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “hold” rating on the stock.
  • 10/29/2017 – Stryker was given a new $166.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 10/27/2017 – Stryker had its price target raised by analysts at Barclays PLC from $137.00 to $148.00. They now have an “underweight” rating on the stock.
  • 10/27/2017 – Stryker had its price target raised by analysts at Canaccord Genuity from $155.00 to $162.00. They now have a “buy” rating on the stock.
  • 10/27/2017 – Stryker had its price target raised by analysts at Stifel Nicolaus from $158.00 to $168.00. They now have a “buy” rating on the stock.
  • 10/27/2017 – Stryker had its price target raised by analysts at Wells Fargo & Company from $160.00 to $166.00.
  • 10/27/2017 – Stryker had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $156.00 price target on the stock.
  • 10/27/2017 – Stryker had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $161.00 price target on the stock.
  • 10/24/2017 – Stryker was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Stryker announced the voluntary product recall of the Oral Care lineup recently. The recall is likely to adversely impact the company’s sales and operating income. Moreover, volatility in foreign currency exchange is likely to impede revenue growth. Stryker also faces supply-side headwinds and has been grappling with issues in the spine business for long. On a positive note, Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues. An upbeat guidance for the full year instills investor confidence on the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. Stryker has had an impressive run on the bourse over the last year, trading above the broader industry.”
  • 10/16/2017 – Stryker was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Stryker announced the voluntary product recall of the Oral Care lineup recently. The recall is likely to adversely impact the company’s sales and operating income. Moreover, volatility in foreign currency exchange is likely to impede revenue growth. Stryker also faces supply-side headwinds and has been grappling with issues in the spine business for long. On a positive note, Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues. An upbeat guidance for the full year instills investor confidence on the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. Stryker has had an impressive run on the bourse over the last year, trading above the broader industry.”
  • 10/6/2017 – Stryker was given a new $160.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.

Stryker Corporation (SYK) traded down $0.33 on Tuesday, reaching $152.03. The company’s stock had a trading volume of 982,438 shares, compared to its average volume of 1,181,520. The stock has a market cap of $58,332.41, a P/E ratio of 24.70, a P/E/G ratio of 2.45 and a beta of 0.78. Stryker Corporation has a one year low of $111.22 and a one year high of $160.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. Stryker’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period last year, the business posted $1.39 EPS. equities analysts anticipate that Stryker Corporation will post 6.47 EPS for the current year.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the sale, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.40% of the company’s stock.

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.